First of multiple agreements being explored by Novartis to leverage manufacturing capacity and capabilities to address pandemic, supporting global supply of COVID-19 vaccine Initial agreement signed with BioNTech to use Novartis manufacturing plant in …
Novartis leprosy medicine donation program with WHO extended to 2025Program has already treated over 7 million patients since 2000New evidence from contact tracing and preventive treatment program shows route to accelerate elimination Basel, January 2…
Media ReleasesDownload the media releaseEnglish (PDF 0.2 MB ) | Deutsch (PDF 0.2 MB) | Français (PDF 0.2 MB)Condensed financial …
Novartis ranked second in the 2021 Access to Medicine Index (ATMIndex), maintaining the same leading position as in 2018, in recognition of its long-standing efforts to improve …
Full year net sales from continuing operations¹ up 3% (cc², +3% USD): Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Zolgensma (reaching USD 0.9 billion), Cosentyx (+13% cc), Ilaris (+31% cc) and the Xiidra acquisition (+95% …
COVID-19 was a catalyst for change in healthcare during 2020 – an accelerator for digital health.2021 looks set to continue the revolution – exploiting ‘an explosion of interest, traction and scale’ in the potential for digital innovation to meet globa…
Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients Combined funding commitment of GBP 2.8 million (USD 3.6 million) over…
Dear SMA community,One year ago we launched a global Managed Access Program (MAP), the first for a one-time gene therapy, to make Zolgensma® (onasemnogene abeparvovec) available to eligible patients with spinal muscular atrophy (SMA) who are under the …
Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines1 Currently there are limited approved therapies for patients with CSU…
Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growthNovartis secures development and commercialization rights in North America, Europe, and …